Catalent Appoints New Global Account Director

Catalent Appoints New Global Account Director

Date: 10/27/2010

Somerset, NJ, October 27, 2010 — Catalent Pharma Solutions announced the appointment of Mark Bridgewater to the position of Global Account Director. In this role, Mr. Bridgewater will be responsible for developing Catalent’s sales strategy for some key global customer accounts. He will be based in Switzerland.

Prior to joining Catalent, Mr. Bridgewater was the Head of Global Contract Manufacturing Services for Wockhardt Limited, where he was responsible for developing their world-wide contract manufacturing business. This included integrating Wockhardt’s Indian and US facilities network, leading a turnaround of their global business as well as spearheading the company’s global account and management effort. Prior to that, Mr. Bridgewater was a Senior Business Manager for Patheon S.p.A. in Italy, where he led their international business. Earlier in his career, Mr. Bridgewater was Commercial Manager for INyX, a small UK-based contract manufacturing organization, and Celestica Limited, a leading-edge electronics company.

Mr. Bridgewater holds a Bachelor of Arts degree in Economics from the University of Staffordshire.

“As Catalent continues to invest in talent to serve its major global accounts, I am excited to have Mark join the Catalent team. He brings significant experience to Catalent, having worked in a range of commercial roles over the years,” said Will Downie, Senior Vice President of Global Sales and Marketing for Catalent.

About Catalent

Headquartered in Somerset, New Jersey, Catalent Pharma Solutions is a leading provider of advanced dose form and packaging technologies, and development, manufacturing and packaging services for pharmaceutical, biotechnology and consumer healthcare companies in nearly 100 countries. Catalent applies its local market expertise and technical creativity to advance treatments, change markets and enhance patient outcomes. Catalent employs approximately 9,000 people at 29 facilities worldwide and in fiscal 2010 generated more than $1.7 billion in annual revenue. For more information, visit .

more products. better treatments. reliably supplied.™